Global Human Immunodeficiency Virus Type-1 麻豆原创 Research Report 2024

Publication ID:

PB508243661

Publication Date:

August 7, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global Human Immunodeficiency Virus Type-1 market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Human Immunodeficiency Virus Type-1 is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Human Immunodeficiency Virus Type-1 is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Human Immunodeficiency Virus Type-1 in Hospital Pharmacies is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Human Immunodeficiency Virus Type-1 include Roche, Bristol Myers Squibb, Merck & Co. Inc., GSK, Pfizer, Viatris, Sanofi, AstraZeneca, Novartis, Bayer, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Human Immunodeficiency Virus Type-1, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Immunodeficiency Virus Type-1.
The Human Immunodeficiency Virus Type-1 market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Immunodeficiency Virus Type-1 market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Immunodeficiency Virus Type-1 companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Roche
Bristol Myers Squibb
Merck & Co. Inc.
GSK
Pfizer
Viatris
Sanofi
AstraZeneca
Novartis
Bayer
Segment by Type
Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
Protease Inhibitors (PIs)
Integrase Inhibitor
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Human Immunodeficiency Virus Type-1 company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Human Immunodeficiency Virus Type-1 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
1.2.3 Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
1.2.4 Protease Inhibitors (PIs)
1.2.5 Integrase Inhibitor
1.2.6 Others
1.3 麻豆原创 by Application
1.3.1 Global Human Immunodeficiency Virus Type-1 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Human Immunodeficiency Virus Type-1 麻豆原创 Perspective (2019-2030)
2.2 Global Human Immunodeficiency Virus Type-1 Growth Trends by Region
2.2.1 Global Human Immunodeficiency Virus Type-1 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Human Immunodeficiency Virus Type-1 Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Human Immunodeficiency Virus Type-1 Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Human Immunodeficiency Virus Type-1 麻豆原创 Dynamics
2.3.1 Human Immunodeficiency Virus Type-1 Industry Trends
2.3.2 Human Immunodeficiency Virus Type-1 麻豆原创 Drivers
2.3.3 Human Immunodeficiency Virus Type-1 麻豆原创 Challenges
2.3.4 Human Immunodeficiency Virus Type-1 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Human Immunodeficiency Virus Type-1 Players by Revenue
3.1.1 Global Top Human Immunodeficiency Virus Type-1 Players by Revenue (2019-2024)
3.1.2 Global Human Immunodeficiency Virus Type-1 Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Human Immunodeficiency Virus Type-1 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Human Immunodeficiency Virus Type-1 Revenue
3.4 Global Human Immunodeficiency Virus Type-1 麻豆原创 Concentration Ratio
3.4.1 Global Human Immunodeficiency Virus Type-1 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Human Immunodeficiency Virus Type-1 Revenue in 2023
3.5 Global Key Players of Human Immunodeficiency Virus Type-1 Head office and Area Served
3.6 Global Key Players of Human Immunodeficiency Virus Type-1, Product and Application
3.7 Global Key Players of Human Immunodeficiency Virus Type-1, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Human Immunodeficiency Virus Type-1 Breakdown Data by Type
4.1 Global Human Immunodeficiency Virus Type-1 Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Human Immunodeficiency Virus Type-1 Forecasted 麻豆原创 Size by Type (2025-2030)
5 Human Immunodeficiency Virus Type-1 Breakdown Data by Application
5.1 Global Human Immunodeficiency Virus Type-1 Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Human Immunodeficiency Virus Type-1 Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Human Immunodeficiency Virus Type-1 麻豆原创 Size (2019-2030)
6.2 North America Human Immunodeficiency Virus Type-1 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Human Immunodeficiency Virus Type-1 麻豆原创 Size by Country (2019-2024)
6.4 North America Human Immunodeficiency Virus Type-1 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Human Immunodeficiency Virus Type-1 麻豆原创 Size (2019-2030)
7.2 Europe Human Immunodeficiency Virus Type-1 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Human Immunodeficiency Virus Type-1 麻豆原创 Size by Country (2019-2024)
7.4 Europe Human Immunodeficiency Virus Type-1 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Human Immunodeficiency Virus Type-1 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Human Immunodeficiency Virus Type-1 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Human Immunodeficiency Virus Type-1 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Human Immunodeficiency Virus Type-1 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Human Immunodeficiency Virus Type-1 麻豆原创 Size (2019-2030)
9.2 Latin America Human Immunodeficiency Virus Type-1 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Human Immunodeficiency Virus Type-1 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Human Immunodeficiency Virus Type-1 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Human Immunodeficiency Virus Type-1 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Human Immunodeficiency Virus Type-1 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Human Immunodeficiency Virus Type-1 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Human Immunodeficiency Virus Type-1 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Human Immunodeficiency Virus Type-1 Introduction
11.1.4 Roche Revenue in Human Immunodeficiency Virus Type-1 Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Bristol Myers Squibb
11.2.1 Bristol Myers Squibb Company Details
11.2.2 Bristol Myers Squibb Business Overview
11.2.3 Bristol Myers Squibb Human Immunodeficiency Virus Type-1 Introduction
11.2.4 Bristol Myers Squibb Revenue in Human Immunodeficiency Virus Type-1 Business (2019-2024)
11.2.5 Bristol Myers Squibb Recent Development
11.3 Merck & Co. Inc.
11.3.1 Merck & Co. Inc. Company Details
11.3.2 Merck & Co. Inc. Business Overview
11.3.3 Merck & Co. Inc. Human Immunodeficiency Virus Type-1 Introduction
11.3.4 Merck & Co. Inc. Revenue in Human Immunodeficiency Virus Type-1 Business (2019-2024)
11.3.5 Merck & Co. Inc. Recent Development
11.4 GSK
11.4.1 GSK Company Details
11.4.2 GSK Business Overview
11.4.3 GSK Human Immunodeficiency Virus Type-1 Introduction
11.4.4 GSK Revenue in Human Immunodeficiency Virus Type-1 Business (2019-2024)
11.4.5 GSK Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Human Immunodeficiency Virus Type-1 Introduction
11.5.4 Pfizer Revenue in Human Immunodeficiency Virus Type-1 Business (2019-2024)
11.5.5 Pfizer Recent Development
11.6 Viatris
11.6.1 Viatris Company Details
11.6.2 Viatris Business Overview
11.6.3 Viatris Human Immunodeficiency Virus Type-1 Introduction
11.6.4 Viatris Revenue in Human Immunodeficiency Virus Type-1 Business (2019-2024)
11.6.5 Viatris Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Details
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Human Immunodeficiency Virus Type-1 Introduction
11.7.4 Sanofi Revenue in Human Immunodeficiency Virus Type-1 Business (2019-2024)
11.7.5 Sanofi Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Details
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Human Immunodeficiency Virus Type-1 Introduction
11.8.4 AstraZeneca Revenue in Human Immunodeficiency Virus Type-1 Business (2019-2024)
11.8.5 AstraZeneca Recent Development
11.9 Novartis
11.9.1 Novartis Company Details
11.9.2 Novartis Business Overview
11.9.3 Novartis Human Immunodeficiency Virus Type-1 Introduction
11.9.4 Novartis Revenue in Human Immunodeficiency Virus Type-1 Business (2019-2024)
11.9.5 Novartis Recent Development
11.10 Bayer
11.10.1 Bayer Company Details
11.10.2 Bayer Business Overview
11.10.3 Bayer Human Immunodeficiency Virus Type-1 Introduction
11.10.4 Bayer Revenue in Human Immunodeficiency Virus Type-1 Business (2019-2024)
11.10.5 Bayer Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Roche
Bristol Myers Squibb
Merck & Co. Inc.
GSK
Pfizer
Viatris
Sanofi
AstraZeneca
Novartis
Bayer

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.